FDA Brief

Warning letters Devices

FDA warning letter to

Getsch+Hiller Medizintechnik GmbH

High riskIssued Dec 27, 2022Posted Feb 7, 2023Center for Devices and Radiological Health

FDA warned Getsch+Hiller about unapproved reusable laparoscopic tips and missing quality records at its German plant.

What happened

FDA inspected the Tuttlingen, Nendingen, Germany facility from July 18, 2022 through July 21, 2022. It found no design history file for reusable-tip laparoscopic instruments intended for the U.S., raw materials used without incoming acceptance, and reusable tips marketed beyond the single-use clearance in K171523.

What FDA found

  1. FDA says the company did not establish a design history file for its Class II monopolar laparoscopic instruments with reusable tips intended for the U.S. market.

    21 CFR 820.30(j)
  2. FDA says raw materials that had not gone through incoming acceptance were labeled as approved and staged next to approved materials used to make devices.

    21 CFR 820.80(b)
  3. FDA says the monopolar laparoscopic instruments lack an approved premarket approval application or investigational device exemption.

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  4. FDA says the company marketed reusable tip inserts after its clearance covered only single-use tips, a significant change requiring a new 510(k).

    section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)

What FDA wants

FDA asks the company to respond in writing within 15 business days with specific steps, documentation of corrections and corrective actions, and a timetable for any planned actions.

Who should pay attention

  • U.S. hospitals and surgical centers using laparoscopic instruments
  • distributors and importers of German medical devices
  • device quality teams managing design and incoming acceptance records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  4. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk